Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin.
Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
- Global LAG 3 Inhibitors Market Dynamics
- Clinical Approaches to Target LAG 3 Inhibitors
- Number of LAG 3 Inhibitors Drug In Trials
- LAG 3 Inhibitors Approved Patent Insight
- LAG 3 Inhibitors Trials By Phase, Company, Country, Indication
- Company Agreement/Partnership/Deals For Ongoing Trials
- LAG-3 Targeted Approach in Cancer Therapy
- Therapeutic Approaches for Novel LAG-3 Targeted Therapy
- Global LAG 3 Inhibitor Market Future Outlook
Download Report:
Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin. Metastatic melanoma is the deadliest form of melanoma and occurs when cancer spreads beyond the surface of skin to other organs. Till date, a cocktail of therapies have been approved which have improved the outcomes for patients with advanced melanoma. However, there are still many patients who do not get benefit from these treatment or whose cancer relapse after sometime. Therefore, there is surge in research and development activities for these unmet patients.
Researchers have recently identified lymphocyte activation gene-3 (LAG-3) which is a member of the immunoglobulin superfamily. In cancer cells, lymphocyte activation gene-3 is expressed on the cell membranes of TIL, activated CD4+ and CD8+ T-cells, as well as Tregs. Further, it is also expressed on NK cells, B-cells, and dendritic cells. The interaction of LAG-3 with MHC-II inhibits the binding of same MHC molecule to TCR and CD4, thus directly hindering TCR signaling in immune response. Studies have shown that abberant LAG-3 expression is associated with broad range of cancers including melanoma, non-small cell lung cancer, colorectal cancer, breast cancer, head and neck cancer, and others. Therefore, considerable investments have been done by pharmaceutical giants to develop novel LAG-3 inhibitor as an alternative to cancer immunotherapy.
On March 18, 2022 US FDA has granted approval to the fixed-dose combination of relatlimab (LAG-3 inhibitor) plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma. The FDA’s decision to approve the combination is based on findings from the hase 2/3 Relativity-047 trial in which relatlimab plus nivolumab demonstrated a 22% reduction in risk of progression or death and numerically improved overall survival rates compared to nivolumab alone. Furthermore, relatlimab in combination with nivolumab has shown manageable safety with no new or unexpected safety signals. The combination is sold under the trade name Opdualag and is marketed by Bristol Myers Squibb. The introduction of LAG-3 inhibitor is expected to transform the cancer immunotherapy approach owing to their ability to overcome the limitation of drug resistance.
Apart from Relatlimab, the pipeline of novel LAG-3 inhibitor drugs includes more than 20 drugs which are mainly present in phase-I/II clinical trials. The major drugs in the development include IMP701, FS118, TSR-033, Eftilagimod Alpha, Tebotelimab, ABL501, and several others. Apart from cancer, LAG-3 also have role in wide range of therapeutic conditions including diabetes, multiple sclerosis, Parkinson, infection, and other autoimmune disorders. Several ongoing clinical trials are evaluating the role of targeting LAG-3 as monotherapy or in combination with other checkpoint inhibitors. The forthcoming years is expected to witness rapid approval of LAG-3 inhibitors in wide range of therapeutic indications which will further propel the growth of market.
As per our report findings, the global lymphocyte activation gene-3 market is expected to surpass US$ XX Billion by 2028. Increasing prevalence of cancer and other chronic diseases, growing regulatory approvals and launch of therapies and increasing research collaborations for the development of robust drug pipeline are the major factors driving the growth of global lymphocyte activation gene-3 market over the forecast period. The major players in the market are Bristol Myers Squibb, Innovent, Macrogenics, GlaxoSmithKline, Novartis, Nanobiotix, and F-Star Therapeutics.
Our report provides comprehensive insights on the ongoing research and development in lymphocyte activation gene-3 inhibitor market along with the major companies competing in the market. Moreover, it provides crucial strategies that are helping them to expand their market share. In addition, various favorable parameters and restrains to the growth of market are also mentioned in the report.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366